Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Compound monograph

Draft monograph: Hexarelin

Consultation on the draft monograph for Hexarelin, which the assessment committee released for public comment before ratification. The draft grades the compound's principal assessed outcome at very low certainty and states the basis for that rating in section…

Document identifier
CEI-CP-055
Series
Public comment period
Version
1.0
Published
27 Aug 2024
Last reviewed
27 Aug 2024
Next review
27 Aug 2025
Identifier
10.71829/cei.cp.55
Certainty
Not rated
Cycle
2024 Q3
Window
14 Jul 2024 – 13 Aug 2024
Status
Closed
Submissions
7

§1Consultation and window

§1.1Window

Opened
14 July 2024
Closed
13 August 2024
Duration
30 days
Status
Closed — the disposition is published
Document under consultation
Monograph: Hexarelin
Submissions received
7

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is the very low certainty rating for the principal assessed outcome correctly drawn from the contributing evidence?
  2. Are the evidence gaps recorded in section 9 complete, and is any material gap omitted?
  3. Is the analytical section proportionate to what a reader would need in order to interpret a certificate for this compound?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

Amendments arising from the consultation were applied before ratification and are recorded in the monograph's amendment log. Each amendment is traceable to a numbered submission on the disposition page.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.